NVCT Stock — Nuvectis Pharma Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.

Source: 10-K FY2025 via SEC EDGAR

Share price

$20.91

Market cap

$719.1M

Cash

$140.7M

Enterprise value

$578.4M

Balance sheet

Cash	$140.7M
Debt	$0.0M
Net cash	$140.7M
Enterprise value	$578.4M
Basic shares	32.6M shares
Fully diluted shares	32.7M shares
Fully diluted market cap	$684.2M
Cash per share	$4.32
Quarterly burn	$4.5M
Cash runway	4.9 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

32.6M

Pre-funded warrants

0.0M

Options

0.0M

RSUs

0.0M

Warrants

0.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

32.7M

Cap table as of 2026-09-30.

Price history

Loading NVCT daily closes…

Loading price history…

Next catalyst

NXP900 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	NXP900 Phase 1b of NXP900 + osimertinib in EGFR+ NSCLC	Phase 1b	EGFR+ NSCLC	Q4 2026
Jan 12 - Feb 23 in 9 wks	NXP900	Phase 1	EGFR Mutation Positive Non-small Cell Lung Cancer; EGFR Mutated Non-small Cell Lung Cancer Patients	—
Apr 12 - May 24 in 5 mo	NXP900	Phase 1	Advanced Solid Tumor; NSCLC (Non-small Cell Lung Cancer); Renal Cancer	—
Sep 12 - Oct 24 in 10 mo	NXP900	Phase 1	ALK Positive; ALK Positive Non-small Cell Lung Cancer; NSCLC	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NXP100

Phase 3 · Active Modality: small molecule

Aliases HSK39297

Target Factor B (complement)

Partnerships Haisco Pharmaceutical Group Co: June 2026 license of exclusive worldwide (excluding China) development, manufacturing, and commercial rights (milestones + royalties on net sales)

Indications

IgA nephropathy (IgAN) (Phase 3)
Lupus nephritis (LN) (Phase 2)

Status note Oral, once-daily, potent and selective small-molecule Factor B inhibitor for complement-related conditions. Phase 3 study for IgAN and Phase 2 study in LN ongoing in China; filing reports cross-trial activity similar to iptacopan with a similar safety profile.

NXP200

Stage not disclosed · Active Modality: small molecule

Aliases HSK42360

Target BRAF

Partnerships Haisco Pharmaceutical Group Co: June 2026 license of exclusive worldwide (excluding China) development, manufacturing, and commercial rights

Indications

Solid tumors (multiple) (Stage not disclosed)
Primary brain cancer (Stage not disclosed)

Status note Paradox-breaker BRAF serine/threonine kinase inhibitor. Described in the filing as clinical-stage, but no trial phase is stated. Positioned for multiple solid tumor types and primary brain cancer, with potential to address resistance to first-generation BRAF inhibitors.

NXP900

Phase 1 · Active Modality: small molecule

Target YES1 / SRC kinases

Partnerships University of Edinburgh: exclusive license to composition-of-matter patent family (Aug 2021)

Indications

Solid tumors (Phase 1)

Status note Once-daily oral inhibitor of YES1 and SRC kinases. Phase 1a supported once-daily dosing; ongoing Phase 1b single-agent study in specific tumor types, Phase 1b combination with osimertinib (commenced December 2025), and a combination study with lorlatinib (ALK inhibitor) pending commencement.

NXP800

Phase 1 · Terminated

Partnerships CRT Pioneer Fund: worldwide exclusive license agreement (May 2021); milestones to ICR

Indications

Ovarian cancer (Phase 1)

Status note Following completion of the Phase 1b study in ovarian cancer (final clinical data update July 2025), the company decided to cease clinical development of NXP800 and is evaluating the feasibility of development in other cancer types.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NXP900
Lead indication	EGFR Mutation Positive Non-small Cell Lung Cancer
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07315113	Phase 1	Recruiting	Sponsor	NVCT	—	EGFR Mutation Positive Non-small Cell Lung Cancer; EGFR Mutated Non-small Cell Lung Cancer Patients	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT05873686	Phase 1	Recruiting	Sponsor	NVCT	—	Advanced Solid Tumor; NSCLC (Non-small Cell Lung Cancer); Renal Cancer	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT07784959	Phase 1	Recruiting	Sponsor	NVCT	—	ALK Positive; ALK Positive Non-small Cell Lung Cancer; NSCLC	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Nuvectis Pharma, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	1,550,000	+1,550,000	1.29%	2026-08-14
Perceptive Advisors	1,000,000	+1,000,000	0.29%	2026-08-14
Sphera Biotech	382,945	+382,945	1.01%	2026-08-14
Stonepine Capital	40,000	+40,000	0.56%	2026-08-17
DAFNA Capital	20,000	+20,000	0.07%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

NVCT — Nuvectis Pharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NVCT — Nuvectis Pharma Inc.